The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
CAR-T Meeting 2026 | The upcoming EBMT-EHA European CAR T-cell meeting 2026: sharing updates in CAR-T & cellular therapy
In this video, Alex Rampotas, MBBS, MRCP, University College London, London, UK, invites viewers to register for the upcoming EBMT-EHA 8th European CAR T-cell meeting, taking place in Palma de Mallorca, Spain, and online on February 12-14, 2026. Dr Rampotas highlights the importance of this event as a platform for exchanging ideas and showcasing new data in the field of CAR-T and cellular therapy, which is currently undergoing a revolution with novel approaches being explored and expansion into further indications. This interview took place virtually.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So the CAR T-cell meeting is an exciting opportunity for people working on CAR T-cell therapies, people doing research and people who are interested in this fascinating technology to come together, see the new data and be able to exchange ideas. I think the CAR T-cell field is undergoing a revolution. I think it has gone up and down in cycles, but at the moment, I think we are at a very pivotal moment...
So the CAR T-cell meeting is an exciting opportunity for people working on CAR T-cell therapies, people doing research and people who are interested in this fascinating technology to come together, see the new data and be able to exchange ideas. I think the CAR T-cell field is undergoing a revolution. I think it has gone up and down in cycles, but at the moment, I think we are at a very pivotal moment. We have seen CAR T-cells expanding into autoimmune diseases, which is fascinating, no one was expecting that a few years ago.
Also, we see the first successful trials on CAR T-cell therapy against solid tumors, which obviously opens a whole different area of possibilities and applications for CAR T-cell technology. And even in hematological tumors, we have CAR T-cells now expanding into myelofibrosis and MPNs, which is also very exciting.
But on top of all that, CAR T-cells as a scientific piece of therapy are fascinating because they can be armored, they can be changed to do more things. It’s a completely new way of treating diseases. And on top of that, one of the main obstacles so far has been the very expensive way that we need to manufacture them and the lengthy process in terms of treating patients. Well, it looks like we may have an avenue to overcome that now, because we had the first successful publications and trials of using in vivo CAR T-cell therapies, and I’m very excited to see the up to date data at this meeting on that.
I think for anyone interested in the field of oncology, hematology, gene therapy or cellular therapies, this meeting is the place to be, and I would be very excited to engage with all of you and connect. So I look forward to seeing everyone in Mallorca, Spain, along with the rest of the EBMT and EHA members.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
